Belpointe Asset Management
BEAM icon

Belpointe Asset Management’s Beam Therapeutics BEAM Stock Holding History

Belpointe Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-475
Closed -$14.5K – 860
2023
Q1 		$14.5K Sell
475
-2,350
-83% -$92.7K ﹤0.01% 2500
2022
Q4 		$110K Sell
2,825
-50
-2% -$2.24K 0.01% 1187
2022
Q3 		$137K Buy
+2,875
New +$164K 0.01% 999
2022
Q2 		– Sell
-2,400
Closed -$138K – 1142
2022
Q1 		$138K Sell
2,400
-35
-1% -$2.3K 0.01% 1077
2021
Q4 		$194K Hold
2,435
– – 0.01% 912
2021
Q3 		$212K Buy
2,435
+8
+0.3% +$804 0.01% 829
2021
Q2 		$312K Hold
2,427
– – 0.02% 652
2021
Q1 		$194K Buy
2,427
+68
+3% +$6.47K 0.02% 762
2020
Q4 		$193K Buy
+2,359
New +$116K 0.02% 704

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belpointe Asset Management's BEAM Position: Q2 2023 in Review

Belpointe Asset Management sold out of Beam Therapeutics (BEAM) in Q2 2023, closing a stake of 475 shares — an estimated $14.5K sold.

Belpointe Asset Management first reported a position in BEAM in Q4 2020 and held it in 9 quarters. The position peaked at $312K in Q2 2021. 193 funds tracked by Wall St. Rank hold BEAM as of Q2 2023.

  • Belpointe Asset Management reported no remaining Beam Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 475 Beam Therapeutics shares in Q2 2023, an estimated $14.5K.
  • Belpointe Asset Management first reported a position in Beam Therapeutics in Q4 2020 and held it in 9 quarters.
  • Belpointe Asset Management's Beam Therapeutics position peaked at $312K in Q2 2021.
  • 193 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.